Tomorrow's Medicine
Delivered Today.
TadbeerPharma applies computational chemistry to identify advanced, off-patent therapeutics unavailable in Afghanistan — then navigates full AFDA registration and deploys across all 34 provinces.
Our competitive moat is scientific and regulatory — not logistical. We solve the hard problem: bringing drugs that exist in global markets into Afghan healthcare at a fraction of originator cost.
Three Problems.
One Integrated Solution.
Most pharmaceutical companies in developing markets solve logistics. We solve science, regulation, and logistics — in that order.
Computational Discovery
We screen hundreds of molecular candidates using computational chemistry tools to identify off-patent APIs with proven efficacy, strong bioequivalence data, and viable manufacturing pathways. Only candidates meeting our criteria proceed to registration.
AFDA Registration
Navigating the Afghan Food & Drug Authority requires deep institutional knowledge. Our regulatory team prepares complete CTD-format dossiers, manages the submission lifecycle, and coordinates directly with AFDA to move registrations efficiently.
National Deployment
Once registered, medicines reach all 34 provinces through our cold-chain-capable distribution network. We operate from central Kabul hubs with end-to-end visibility — from manufacturer to point of care.
From Molecule to Market
A rigorous, four-stage process that turns global scientific knowledge into medicines Afghan patients can access and afford.
Discover
Computational screening of 140+ molecular candidates against our criteria: off-patent status, bioequivalence data quality, API stability, and manufacturability within our cost targets.
Register
Full CTD-format dossier preparation including analytical chemistry reports, stability studies, bioequivalence documentation, and labelling. Submitted directly to AFDA through our regulatory team.
Deploy
Cold-chain distribution from manufacturer to Kabul hub to provincial health facilities. Real-time inventory visibility and temperature monitoring across all 34 provinces.
Comply
Every product is WHO-GMP certified. Post-market surveillance, pharmacovigilance reporting, and ongoing AFDA relationship management ensure continued compliance.
A 40 Million Person Market With Almost No Modern Generic Supply
Afghanistan's pharmaceutical market is overwhelmingly dependent on branded and Indian generic imports. The majority of advanced therapeutics — biologics, cardiovascular agents, oncology-adjacent drugs — are either unregistered or unavailable at any price point.
AFDA has been actively modernising its registration framework under WHO support, creating a real pathway for compliant generic manufacturers to enter the market. TadbeerPharma was built to exploit this regulatory window — with the scientific rigour to get products registered and the operational capability to reach patients once they are.
Compliance Is Structural,
Not Supplementary
Every manufacturer in our network holds a current WHO-GMP certificate. Every product is AFDA-registered before a single unit is deployed. There is no shortcut — and we would not take one if there were.
WHO-GMP Certified
All partner manufacturers hold current Good Manufacturing Practice certification under WHO standards.
AFDA Registered
Every product receives full AFDA marketing authorisation before deployment. No exceptions.
Bioequivalence Proven
All APIs are supported by bioequivalence studies meeting international pharmacopoeia standards.
Pharmacovigilance
Ongoing post-market surveillance and adverse event reporting per AFDA and WHO requirements.